secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001171843-23-006910
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics Q3 net loss $5.1M; cash $6.4M; agenT-797 shows durable solid tumor benefit
--------------------------------------------------------------------------------

- Cash $6.4M at Sep 30, 2023, down from $19.6M at Dec 31, 2022; Q3 cash used in ops $4.2M.
- Q3 net loss $5.1M ($0.15/sh); 9-month net loss $17M ($0.50/sh), vs $20.2M ($0.60/sh) year ago.
- AgenT-797: >30% disease stabilization/biomarker response in heavily pretreated solid tumors; durable gastric cancer response.
- Randomized Phase 2 trial of agenT-797 in 2L gastric cancer to launch this year, externally funded, led by MSKCC.
- R&D expense down to $3.4M ($6.2M in Q3 2022) as company focuses iNKT platform and cGMP manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184323006910/0001171843-23-006910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184323006910/f8k_110923.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer